Plain-English translation of NCT05695508 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing teclistamab, , and — three new medications — combined with standard multiple myeloma treatments. The study includes different treatment combinations to see which works best and is safest for people who have just been diagnosed with this blood cancer. Researchers want to learn whether these new medications can improve how well patients respond to treatment and live longer.
Multiple myeloma is a serious blood cancer that currently requires intensive treatment. Even with existing therapies, patients eventually relapse. This medication is designed to work in a new way against cancer cells, and researchers believe combining it with proven treatments may help patients achieve deeper remissions and better long-term outcomes.
You likely qualify if…
You likely don't qualify if…
Depending on which treatment arm you join, you will receive induction therapy (initial intensive treatment) for about 6 months, followed by a stem cell transplant (for most participants) and then maintenance therapy (ongoing treatment) for up to 18 months. You will receive injections of the new medication along with other standard myeloma drugs. Throughout the trial, you'll have regular clinic visits for blood tests, imaging scans, and safety checks to monitor how you're responding and to watch for side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Germany